Liege, Belgium, 06 November 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces today that it has published and issued an invitation to its announced1 and conditionally planned for extraordinary securities holders’ meeting that will be held on Thursday, 23 November 2023, at 2:00 PM (CET).
The notice for the extraordinary general meeting (EGM), including a description of the formalities to participate at the meeting, is available on the website investors.mithra.com.
As referred in the meetings’ invitation published in the Belgian press, the right to participate in the EGM and to vote is subject to the prior registration of the shares under the relevant shareholder’s name by 17 November 2023 at midnight (CET) (the “Record Date“), either by way of registration on the company’s share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the EGM. Only persons who are shareholders on the Record Date are entitled to vote at the EGM.
The shareholders must indicate their willingness to participate in the EGM by 17 November 2023 at the latest. This must be done by email to email@example.com, or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges in 4000 Liège.
Right to ask questions
The directors will answer questions that are asked by the shareholders in writing, before the meeting and concerning the agenda, in accordance with legal provisions. These questions may be asked prior to the EGM by email via firstname.lastname@example.org or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges in 4000 Liège. These questions must be received by the Company by 17 November 2023 at the latest.
Further information relating to the above-mentioned rights and the modalities for exercising them are available on the Company’s website (www.mithra.com).
Shareholders wishing to be represented at the meeting by a proxy holder must send the completed and signed2 proxy form to the Company on 17 November 2023 at the latest, by email, fax or mail to Mithra’s headquarters.
Further information on the exercise of this right is available on the Company’s website (www.mithra.com). The proxy and voting forms may be obtained on the Company’s website (www.mithra.com) or upon request at the Company’s registered office, or by email to email@example.com.
Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.
All documents concerning the special and extraordinary general meetings that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company’s website (www.mithra.com) as from 06 November 2023. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company’s registered office and/or, upon display of their securities, obtain copies of these documents free of charge.
Requests for copies may also be made, free of charge, by mail (writing) marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to firstname.lastname@example.org.
2 The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended